Rf Ablation Articles & Analysis
23 news found
Roughly 8% of U.S. adults suffer from persistent or chronic back pain. That’s around 65 million people who are prevented from engaging in daily activities. Many are forced to miss days of work due to injury. With rising healthcare costs, many back pain sufferers think that they are left without a real solution, until they try epidural injections. An epidural injection is the infusion of ...
(Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Company has submitted for approval to commence a real-time iCMR-guided ventricular tachycardia (VT) ablation clinical trial. The name of the study is “Vision-MR Ablation of VT” or VISABL-VT. VISABL-VT is a ...
ByImricor
” “Almost all patients with persistent AF in the Cryocure-2 study underwent ablations which combined pulmonary vein isolation with additional lesions, mostly on the posterior wall of the left atrium,” added Lucas Boersma, MD, PhD at St. ...
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application technology for the upper ...
Additionally, the development of our RF ablation electrode and hardware remains on schedule as we expect to complete system prototypes by the end of the third calendar quarter of 2022. We are still targeting submitting for 510(k) clearance for RF ablation in early calendar year 2023. Cost reduction programs are underway for our ...
Additionally, we advanced development of our ablation electrode, and are focused on having complete system prototypes by the end of the third calendar quarter of 2022 and submitting for 510(k) clearance in early 2023. ...
Reddy and Prof. Neužil. Pulsed field ablation is an innovative therapy that uses electric fields to treat heart tissue. ...
The inception of this study highlights Acutus’ unique therapeutic position offering the first and only force sensing gold-tip ablation catheter, AcQBlate Force, designed to deliver either radiofrequency (RF) or PFA therapy – with the added benefit of fully integrating with therapy guidance provided by the novel AcQMap 3D Imaging and Mapping System. ...
Redwood City, CA, October 5, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Dr. John Thoppil is the first physician in the state of Texas to offer its Sonata® Treatment to women with symptomatic uterine fibroids as an office-based procedure at his River Place ...
SAN CARLOS, California, September 20, 2021 — Galaxy Medical announced today the initiation of the SPACE-AF study with enrollment of the first two patients at Southlake Regional Health Centre in Newmarket, Canada. In the study, the CENTAURI Pulsed Electric Field (PEF) ablation system will be used to ablate both the pulmonary veins and posterior walls in patients with persistent atrial ...
These benefits include: a 20% reduction in the smallest ablation size setting, which greatly increases the ability to treat fibroids in tighter anatomical locations; new software advances that allow the surgeon to control all aspects of the ablation from the handpiece without requiring OR staff to separately adjust settings; and changes that enable the surgeon to ...
Redwood City, CA, September 14, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced Anthem, Inc., the largest managed health care company in the Blue Cross Blue Shield Association, has provided positive payer coverage for the Sonata® Treatment. Anthem’s decision creates ...
Redwood City, CA, August 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today a group of 12 surgeons from multiple fibroid treatment centers in Germany, Austria and Switzerland have published a review of symptomatic fibroid treatments, and recommended a treatment algorithm ...
Redwood City, CA, June 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today Blue Cross Blue Shield of Florida (Florida Blue) has released a coverage policy for its Sonata® Procedure.1 The addition of the Florida Blue policy allows another 5 million covered lives in ...
Redwood City, CA, June 3, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Cigna has released a national coverage policy for treatment of uterine fibroids with the Sonata® System.1 Cigna is one of the largest commercial payers in the country with a significant ...
SAN CARLOS, California, April 22, 2021 — Galaxy Medical announced today that the acute results of its Europe-focused ECLIPSE-AF study will be featured during the upcoming EHRA Congress in a innovative Technology presentation on April 25th by Ante Ani , M.D., Electrophysiology Laboratory Director at University Clinical Hospital in Split, Croatia, and primary investigator of the study. The ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in the long bones of ...
Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. This PFA system – comprising a sheath, generator and catheters – is intended to ablate ...
MONTREAL and WALTHAM, Mass., June16, 2020–The Montreal Heart Institute(MHI) and Thermedical®, a developer of thermal-ablation systemsto treat ventricular arrhythmias, today announced the first ablation performed using the groundbreaking Durablate® retractable needle catheter and degassed saline, which together eliminateover98% of the air bubbles that can lead to stroke. Health ...
FDA for its saline enhanced radiofrequency (SERF) ablation system and Durablate catheter in the treatment of ventricular tachycardia (VT). The system uses a new means of biological heat to precisely deliver ablation therapy to the heart.VT is a leading cause of sudden cardiac death worldwide – an event that kills roughly 325,000 U.S. adults each year. ...